Pink Sheet is part of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction
UsernamePublicRestriction

In Brief: Wyeth/Elan Naprelan

Executive Summary

Wyeth/Elan Naprelan: Elan Pharma neurological sales force of 60 reps will begin promoting Naprelan (naproxen controlled-release) to neurologists, and physical medicine and rehabilitation specialists. Wyeth-Ayerst has been marketing the once-daily arthritis pain medication, which uses Elan's Intestinal Protective Drug Absorption System, to general practitioners, family practice and internal medicine physicians since April 1996. Naprelan is the first product to be marketed by the Elan Pharma neurological sales force. The group plans to promote Elan subsidiary Athena's anti-epileptic Diastat (diazepam gel), which the firm expects to be approved later this year...
Advertisement
Advertisement
UsernamePublicRestriction

Register

PS030554

Ask The Analyst

Please Note: You can also Click below Link for Ask the Analyst
Ask The Analyst

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts

Cancel